Bedside rapid flu test and zanamivir prescription in healthy working adults: A cost-benefit analysis

PharmacoEconomics

Volumn 21, Issue 3, 2003, Pages 215-224

  Schwarzinger, Michaël ^a   Housset, Bruno ^b   Carrat, Fabrice ^a  

^a HÔPITAL SAINT ANTOINE   (France)

^b CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ERYTHROMYCIN; MACROLIDE; PENICILLIN DERIVATIVE; ZANAMIVIR;

ACCURACY; ARTICLE; CLINICAL TRIAL; CONSULTATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; DECISION THEORY; DISEASE DURATION; ENZYME ASSAY; EPIDEMIC; HEALTH ECONOMICS; HUMAN; IMMUNOASSAY; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS B; PRESCRIPTION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SOCIOECONOMICS; SUPERINFECTION; SYMPTOM; SYSTEMIC THERAPY; TREATMENT OUTCOME; WORKER;

ADULT; ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DECISION TREES; ECONOMICS, PHARMACEUTICAL; FEMALE; GUANIDINES; HUMANS; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PYRANS; SIALIC ACIDS; ZANAMIVIR;

EID: 0037218403     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200321030-00006     Document Type: Article

References (50)

1. Demicheli V, Jefferson T, Rivetti D, et al. Prevention and early treatment of influenza in healthy adults. Vaccine 2000; 18: 957-1030
2. Nichol KL, Mendelman PM, Mallon KP, et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA 1999; 282: 137-44
3. Wilde JA, McMillan JA, Serwint J, et al. Effectiveness of influenza vaccine in health care professionals: a randomized trial. JAMA 1999; 281: 908-13
4. Nichol KL, Lind A, Margolis KL, et al. The effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med 1995; 333: 889-93
5. Nichol KL. Clinical effectiveness and cost effectiveness of influenza vaccination among healthy working adults. Vaccine 1999; 17 Suppl. 1: S67-73
6. Bridges CB, Thompson WW, Meltzer MI, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA 2000; 284: 1655-63
7. Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2002; 51: 1-31
8. Williamson JC, Pegram PS. Respiratory distress associated with zanamivir. N Engl J Med 2000; 342: 661-2
9. Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitors. Lancet 2000; 355: 827-35
10. Carrat F, Tachet A, Rouzioux C, et al. Evaluation of clinical case definitions of influenza: detailed investigation of patients during the 1995-1996 epidemic in France. Clin Infect Dis 1999; 28: 283-90
11. Monto AS, Gravenstein S, Elliott M, et al. Clinical signs and symptoms predicting influenza infection. Arch Intern Med 2000; 160: 3243-7
12. Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
13. Drummond M, O'Brien B, Stoddart G, et al. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford University Press, 1997
14. Data [computer program]. Version 3.0. Williamstown (MA): TreeAge Software, Inc, 2000
15. Hayden FG, Osterhaus AD, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engt J Med 1997; 337: 874-80
16. MIST Study Group. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group [published erratum appears in Lancet 1999; 353: 504 and 1999; 353: 1104]. Lancet 1998; 352: 1877-81
17. Lalezari J, Klein T, Stapleton J, et al. The efficacity and safety of inhaled zanamivir in the treatment of influenza in otherwise healthy and 'high risk' individuals in North America [abstract]. J Antimicrob Chemother 1999; 44 Suppl. A: 42
18. Monto AS, Fleming DM, Henry D, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J Infect Dis 1999; 180: 254-61
19. Makela MJ, Pauksens K, Rostila T, et al. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study. J Infect 2000; 40: 42-8
20. West Midlands Development and Evaluation Service, University of Birmingham. Zanamivir for the treatment of influenza in adults [online]. Available from URL: http://www.nice.org.uk [Assessed 2002 Jul 5]
21. Boivin G, Goyette N, Hardy I, et al. Rapid antiviral effect of inhaled zanamivir in the treatment of naturally occurring influenza in otherwise healthy adults. J Infect Dis 2000; 181: 1471-4
22. Herrmann B, Larsson C, Zweygberg BW. Simultaneous detection and typing of influenza viruses A and B by a nested reverse transcription-PCR: comparison to virus isolation and antigen detection by immunofluorescence and optical immunoassay (FLU OIA). J Clin Microbiol 2001; 39: 134-8
23. Boivin G, Hardy I, Kress A. Evaluation of a rapid optical immunoassay for influenza viruses (FLU OIA test) in comparison with cell culture and reverse transcription-PCR. J Clin Microbiol 2001; 39: 730-2
24. Schultze D, Thomas Y, Wunderli W. Evaluation of an optical immunoassay for the rapid detection of influenza A and B viral antigens. Eur J Clin Microbiol Infect Dis 2001; 20: 280-3
25. Kaiser L, Keene ON, Hammond JM, et al. Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults. Arch Intern Med 2000; 160: 3234-40
26. Keech M, Scott AJ, Ryan PJ. The impact of influenza and influenza-like illness on productivity and healthcare resource utilization in a working population. Occup Med 1998; 48: 85-90
27. Aoki FY, Fleming DM, Griffin AD, et al. Impact of zanamivir treatment on productivity, health status and healthcare resource use in patients with influenza. Zanamivir Study Group. Pharmacoeconomics 2000; 17 (2): 187-95
28. Ellis JS, Fleming DM, Zambon MC. Multiplex reverse transcription-PCR for surveillance of influenza A and B viruses in England and Wales in 1995 and 1996. J Clin Microbiol 1997; 35: 2076-82
29. Fleming DM, Chakraverty P, Sadler C, et al. Combined clinical and virological surveillance of influenza in winters of 1992 and 1993-4. BMJ 1995; 311: 290-1
30. Monto AS, Ohmit SE, Margulies JR, et al. Medical practice-based influenza surveillance: viral prevalence and assessment of morbidity. Am J Epidemiol 1995; 141: 502-6
31. Covalciuc KA, Webb KH, Carlson CA. Comparison of four clinical specimen types for detection of influenza A and B viruses by optical immunoassay (FLU OIA test) and cell culture methods. J Clin Microbiol 1999; 37: 3971-4
32. Hindiyeh M, Goulding C, Morgan H. et al. Evaluation of BioStar FLU OIA assay for rapid detection of influenza A and B viruses in respiratory specimens. J Clin Virol 2000; 17: 119-26
33. Noyola DE, Paredes AJ, Clark B, et al. Evaluation of a neuraminidase detection assay for the rapid detection of influenza A and B virus in children. Pediatr Dev Pathol 2000; 3: 162-7
34. Department of Health and Human Services, Health Care Financing Administration. 42 CFR Parts 410, 411, 414, 415, and 485. Medicare program; revisions to payment policies under the physician fee schedule for calendar year 2000. Fed Regist 1999; 64: 59379-590
35. drug topics red book. Montvale (NJ): Medical Economics Company Inc, 1995
36. Two neuraminidase inhibitors for treatment of influenza. Med Lett Drugs Ther 1999; 41: 91-3
37. Rapid diagnostic tests for influenza. Med Lett Drugs Ther 1999; 41: 121-2
38. US Census Bureau, Current Population Reports, P60-209. Money income in the United States: 1999. Washington (DC): US Government Printing Office, 2000
39. Neu HC. The crisis in antibiotic resistance. Science 1992; 257: 1064-73
40. Cohen ML. Epidemiology of drug resistance: implications for a post-antimicrobial era. Science 1992; 257: 1050-5
41. Gonzales R, Steiner JF, Sande MA. Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians. JAMA 1997; 278: 901-4
42. Mauskopf JA, Cates SC, Griffin AD, et al. Cost effectiveness of zanamivir for the treatment of influenza in a high risk population in Australia. Pharmacoeconomics 2000; 17 (6): 611-20
43. Neuzil KM, Reed GW, Mitchel Jr EF, et al. Influenza-associated morbidity and mortality in young and middle-aged women. JAMA 1999; 281: 901-7
44. Brouwer WB, Koopmanschap MA, Rutten FF. Productivity costs measurement through quality of life?: a response to the recommendation of the Washington Panel. Health Econ 1997; 6: 253-9
45. Brouwer WB, Koopmanschap MA, Rutten FF. Productivity losses without absence: measurement validation and empirical evidence. Health Policy 1999; 48: 13-27
46. Smith AP, Thomas M, Brockman P, et al. Effect of influenza B virus infection on human performance. BMJ 1993; 305: 760-1
47. Gubareva LV, Webster RG, Hayden FG. Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay. Antiviral Res 2002; 53: 47-61
48. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2000; 283: 1016-24
49. Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000; 355 1845-50
50. Carrat F, Sahler C, Rogez S, et al Influenza burden-of-illness: estimates from a national prospective survey of household contact in France. Arch Intern Med 2002; 162: 1842-8